SSO2 Therapy in STEMI to Reduce Infarct Size: A Conversation With Global Thought Leaders
Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. A new FDA approved therapy, TherOx® SSO2 Therapy, has been shown to reduce infarct size by 26% when treated within 6 hours of symptom onset in anterior STEMI patients post-PCI (1).
Pre-clinical studies have also shown that SSO2 addresses microvascular obstruction, which is strongly associated with mortality and hospitalization for HF within 1 year (2, 3).
Learn about this promising new therapy for STEMI patients and hear from global thought leaders about their experiences with it.
1 Stone GW, et al. Circ Cardiovasc Interv; 2; 366-375. Sep 2009.
2 Spears, et al. J Invas Cardiol 2002;14:160-6.
3 DeWaha, et al. European Heart Journal (2017) 38, 3502–3510.
This webinar is supported by:
Welcome and Introduction
Trends in STEMI Outcomes
Overview of TherOx® SSO2 Therapy
Real World Results and Experiences with SSO2 Therapy
Conclusions and Q&A
- To develop an understanding of how SSO2 Therapy works
- Understand the impact of infarct size reduction
- Understand the supporting data for SSO2 Therapy
- Discover experiences with SSO2 Therapy
- Interventional Cardiologists
- Heart Failure Specialists
- Clinical Fellows and Trainees
Dr Yakubov is the John H. McConnell Chair of Advanced Structural Heart Disease, System Medial Chief, Advanced Structural Heart Disease of OhioHealth and Medical Director of Cardiovascular Studies for the OhioHealth Research Institute at Riverside Methodist Hospital, Columbus, Ohio. He has been involved in numerous clinical trials to advance treatment options for cardiovascular disease and structural heart disease. He is a speaker at several annual major cardiovascular conferences and has numerous publications in major medical journals and book chapters. He has been instrumental in the development of new technology for the treatment of structural heart disease.
Dr Richard Schatz is research director of cardiovascular interventions at the Scripps Heart, Lung, and Vascular Center and director of gene and stem cell therapy. A recognized international expert in interventional cardiology, he has published and lectured extensively. His seminal work in coronary stents spurred a revolution in the treatment of coronary artery disease – more than 2 million of them are placed annually worldwide, with an immeasurable impact on relieving mortality and morbidity, improving patients’ lives, and reducing healthcare costs.
Dr Andreas Schäfer currently holds the position of deputy director at Hannover Medical School and specialises in interventional cardiology. Dr Schäfer has been involved in multiple clinical trials and has published extensively in the field of interventional cardiology. In addition, he regularly speaks at conferences and educational events globally.
Dr Burkhoff is currently the Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation. Dr Burkhoff's interest include cardiovascular modelling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices. He is also author of Harvi, an interactive simulation-based application for teaching and researching on ventricular mechanics and hemodynamics.